Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Children Suffering From Grass Pollen Rhinoconjunctivitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female outpatients aged 5 to 17 years.~* Written consent / assent.~* Grass pollen-related allergic rhinoconjunctivitis for at least the last two pollen seasons.~* Sensitised to grass pollen (positive SPT and grass pollen-specific IgE values of at least Class 2).~* Total symptom score on the Retrospective RTSS during the previous pollen season of greater than or equal to 12.~Exclusion Criteria:~* Patients who have received any desensitisation treatment for grass pollen.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- 300 IR (Type: EXPERIMENTAL): 300 IR grass pollen allergen extract tablet
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).